DUBLIN–(BUSINESS WIRE)–The “A Practical Approach to Veterinary Vaccine Development and Registration in the EU (European Union) Training Course (Mar 10th – Mar 11thDUBLIN–(BUSINESS WIRE)–The “A Practical Approach to Veterinary Vaccine Development and Registration in the EU (European Union) Training Course (Mar 10th – Mar 11th

A Practical Approach to Veterinary Vaccine Development and Registration in the EU (European Union) Training Course (Mar 10th – Mar 11th, 2026) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “A Practical Approach to Veterinary Vaccine Development and Registration in the EU (European Union) Training Course (Mar 10th – Mar 11th, 2026)” training has been added to ResearchAndMarkets.com’s offering.

Demand for biologics in veterinary medicine is increasing. However, developing vaccines and successfully obtaining market authorisation brings its own complex and challenging issues.

This course has been designed to give practical advice and guidance on how to successfully develop a veterinary vaccine and achieve market approval in the EU, ensuring that participants gain a comprehensive insight into the necessary requirements.

The programme will take a step-by-step approach to the process and will include a workshop to help delegates gain a better understanding of the requirements in practice. There will be ample time for discussion throughout the two days with our expert faculty and fellow professionals.

Benefits of attending

  • Recognise the key legislation and guidance and how to use this to plan an effective veterinary vaccine development
  • Understand what data you need to generate for your application and how to present this in your dossier
  • Gain an insight into the different routes to market and how to submit your dossier for market approval
  • Learn how and when to seek regulatory advice during development
  • Consider the implications of the ongoing review of the Veterinary Medicines Regulations

Who Should Attend:

This event will be beneficial to all those working with veterinary vaccines from development to market approval.

The programme will be of particular interest to:

  • New entrants to registration departments
  • Veterinary medicinal product manufacturers
  • Registration managers
  • Research and development departments
  • Academics with an interest in commercialising opportunities
  • Personnel from micro/small and medium-sized enterprises (SMEs)

Certifications:

  • CPD: 12 hours for your records
  • Certificate of completion

Key Topics Covered:

Day 1

A practical guide to the EU regulatory framework for veterinary vaccines

  • Regulatory bodies
  • Key legislation and guidance
  • Update on the legislation review

Meeting the requirements of the marketing authorisation dossier – part 2: quality

  • Legislation and guidance
  • Layout and content of the Part 2 dossier

Meeting the requirements of the marketing authorisation dossier – part 3: safety

  • Legislation and guidance
  • Data requirements for the demonstration of safety
  • Layout of the Part 3 dossier

Meeting the requirements of the marketing authorisation dossier – part 4: efficacy

  • Legislation and guidance
  • Data requirements for the demonstration of efficacy
  • Layout of the Part 4 dossier

Day 2

Using the summary of product characteristics (SmPC) as a tool for development

Planning a vaccine development – introduction and workshop

Workshop – groups report back and Q&A

Preparing the dossier submission

  • Marketing authorisation dossier – Part 1: Administrative documentation, DACS and benefit risk assessments and product information
  • Tips on dossier writing and e-submissions

European licensing procedures and regulatory strategy

  • Centralised procedure
  • Decentralised procedure
  • Mutual recognition procedure
  • Regulatory strategy

Seeking regulatory advice and development of novel vaccines

  • Meetings with regulators
  • Scientific advice
  • Innovation Task Force (ITF)

Procedures aimed at promoting innovation and vaccine availability

  • Minor use/minor species (MUMS) classification
  • Small/medium enterprise (SME) designation
  • EMA network strategy 2020

Speakers:

Mel Munro

Management Forum

Mel has worked in regulatory affairs in the Animal Health Industry since 2002. She has been involved in all aspects of veterinary vaccine development and spends most of her time assisting clients with Start-to-Finish projects, taking ideas for veterinary medicines from proof of concept right through to Marketing Authorisations (MA).

On a daily basis Mel is responsible for preparing reports, documents and Dossiers for MA submissions, and for running National, Decentralised and Centralised Procedures. She also provides gap analysis of existing products and strategic advice on new product developments.

Over her career she has been involved in various vaccine development projects ranging from inactivated and live viral and bacterial vaccines, to novel vaccines that include products of rDNA technology and GMO’s.

For more information about this training visit https://www.researchandmarkets.com/r/y6vavs

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Top Crypto Coins To Buy Now As APEMARS ($APRZ) Gains Momentum: These Meme Coins Could Explode After FOMC

Top Crypto Coins To Buy Now As APEMARS ($APRZ) Gains Momentum: These Meme Coins Could Explode After FOMC

In a world where memes, communities, and digital assets collide, a few projects rise above the noise. Today, whispers and attention are gathering around three names
Share
Coinstats2025/12/30 09:15
PBOC sets USD/CNY reference rate at 7.0348 vs. 7.0056 previous

PBOC sets USD/CNY reference rate at 7.0348 vs. 7.0056 previous

The post PBOC sets USD/CNY reference rate at 7.0348 vs. 7.0056 previous appeared on BitcoinEthereumNews.com. On Tuesday, the People’s Bank of China (PBOC) sets
Share
BitcoinEthereumNews2025/12/30 10:18
Taiko Makes Chainlink Data Streams Its Official Oracle

Taiko Makes Chainlink Data Streams Its Official Oracle

The post Taiko Makes Chainlink Data Streams Its Official Oracle appeared on BitcoinEthereumNews.com. Key Notes Taiko has officially integrated Chainlink Data Streams for its Layer 2 network. The integration provides developers with high-speed market data to build advanced DeFi applications. The move aims to improve security and attract institutional adoption by using Chainlink’s established infrastructure. Taiko, an Ethereum-based ETH $4 514 24h volatility: 0.4% Market cap: $545.57 B Vol. 24h: $28.23 B Layer 2 rollup, has announced the integration of Chainlink LINK $23.26 24h volatility: 1.7% Market cap: $15.75 B Vol. 24h: $787.15 M Data Streams. The development comes as the underlying Ethereum network continues to see significant on-chain activity, including large sales from ETH whales. The partnership establishes Chainlink as the official oracle infrastructure for the network. It is designed to provide developers on the Taiko platform with reliable and high-speed market data, essential for building a wide range of decentralized finance (DeFi) applications, from complex derivatives platforms to more niche projects involving unique token governance models. According to the project’s official announcement on Sept. 17, the integration enables the creation of more advanced on-chain products that require high-quality, tamper-proof data to function securely. Taiko operates as a “based rollup,” which means it leverages Ethereum validators for transaction sequencing for strong decentralization. Boosting DeFi and Institutional Interest Oracles are fundamental services in the blockchain industry. They act as secure bridges that feed external, off-chain information to on-chain smart contracts. DeFi protocols, in particular, rely on oracles for accurate, real-time price feeds. Taiko leadership stated that using Chainlink’s infrastructure aligns with its goals. The team hopes the partnership will help attract institutional crypto investment and support the development of real-world applications, a goal that aligns with Chainlink’s broader mission to bring global data on-chain. Integrating real-world economic information is part of a broader industry trend. Just last week, Chainlink partnered with the Sei…
Share
BitcoinEthereumNews2025/09/18 03:34